✦ LIBER ✦

Gefitinib (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells

✍ Scribed by Satoru Shintani; Chunnan Li; Mariko Mihara; Koh-ichi Nakashiro; Hiroyuki Hamakawa

Book ID: 117467952
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 239 KB
Volume: 201
Category: Article
ISSN: 0304-3835
DOI: 10.1016/s0304-3835(03)00464-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

‘Targeting’ the epidermal growth factor

‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)

✍ William Pao; Vincent A. Miller; Mark G. Kris 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 182 KB

ZD1839 (Gefitinib, ‘Iressa’), an epiderm

ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma

✍ Fuminori Teraishi; Shunsuke Kagawa; Takanori Watanabe; Yasuhisa Tango; Takeshi K 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 444 KB

Additive antitumor effects of the epider

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

✍ Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Danilo Millimaggi; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 618 KB

## Abstract Progression from an androgen‐dependent to an androgen‐independent state often occurs in patients with prostate cancer (PCa) who undergo hormonal therapy. We have investigated whether inhibition of the epidermal growth factor receptor (EGFR) signaling pathway affects the antitumor effect

829 The epidermal growth factor receptor

829 The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘iressa’, ZD-1839) and the protein prenyltransferase inhibitor M365408 as potential therapeutics in bladder cancer

✍ J.L. Dominguez-Escrig; J. Kelly; B.R. Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Gefitinib (‘Iressa’, ZD1839), an epiderm

Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines

✍ Satoru Shintani; Chunnan Li; Mariko Mihara; Junya Yano; Nagaaki Terakado; Koh-ic 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 508 KB

Targeted inhibition of the epidermal gro

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells

✍ Alessandro Sgambato; Andrea Camerini; Beatrice Faraglia; Raffaele Ardito; Gabrie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (‘Iressa’), an orally a